Dogwood Therapeutics, Inc. (DWTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Dogwood Therapeutics, Inc. (DWTX) closed at USD 1.27 on 2026-10-14, a change of -79.8 % over the past year, with a market capitalization of USD 42.49M.

Dogwood Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Dogwood Therapeutics, Inc. key figures

Previous close

USD 1.27 (2026-10-14)

1-year change

-79.8 %

Market cap

USD 42.49M

Enterprise value

USD 33.01M

P/E ratio (trailing)

0.60

P/E ratio (forward)

-0.20

EPS (trailing)

2.08

EPS (forward)

-6.37

PEG ratio

n/a

Price to book

0.61

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.58

Employees

8

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Dogwood Therapeutics, Inc. and compare it with other stocks.